MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-05-2025
AxoGen Operating Income 2011-2026 | AXGN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income AxoGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.29 M | -21.5 M | -29.7 M | -25.4 M | -23.2 M | -31.4 M | -20.5 M | -7.95 M | -8.13 M | -9.27 M | -9.8 M | -9.59 M | -7.8 M | -6.97 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.29 M | -31.4 M | -15.3 M |
Quarterly Operating Income AxoGen
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.67 M | -1.66 M | - | -316 K | -428 K | -4.56 M | - | -4.02 M | -6.9 M | -7.34 M | - | -4.86 M | -7.92 M | -11.3 M | - | -6.69 M | -7.15 M | -6.22 M | - | -1.04 M | -8.25 M | -8.51 M | - | -6.11 M | -7.67 M | -10.2 M | - | -4.84 M | -4.82 M | -4.99 M | - | -1.5 M | -1.45 M | -3.2 M | - | -1.18 M | -1.61 M | -2.62 M | - | -1.92 M | -2.15 M | -2.54 M | - | -1.8 M | -2.3 M | -2.99 M | - | -2.28 M | -2.19 M | -2.32 M | - | -2.04 M | -1.59 M | -1.94 M | - | -2.63 M | -1.45 M | -902 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.67 M | -11.3 M | -3.79 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.97 | -1.59 % | $ 644 M |  Israel |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.89 | -2.51 % | $ 135 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 16.95 | -4.48 % | $ 2.42 B | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 312.8 | -0.23 % | $ 8.83 B | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 41.19 | -0.91 % | $ 1.27 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.69 | -9.12 % | $ 138 M |  France |
 |
Bruker Corporation
BRKR
|
253 M | $ 50.26 | 3.85 % | $ 7.49 K | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 91.09 | 3.43 % | $ 134 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 121.01 | -0.61 % | $ 211 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 13.79 | -1.11 % | $ 1.09 B | Israel |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 27.84 | 0.04 % | $ 235 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 165.75 | -3.35 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.81 | -3.78 % | $ 83.2 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 13.82 | -5.67 % | $ 374 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.68 | 0.24 % | $ 122 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 102.68 | 0.67 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
208 M | $ 84.87 | -1.06 % | $ 2.85 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
LivaNova PLC
LIVN
|
129 M | $ 62.45 | 0.55 % | $ 3.39 B |  Britain |
 |
Globus Medical
GMED
|
166 M | $ 92.68 | -0.85 % | $ 12.6 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 11.98 | -3.51 % | $ 923 M | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 1.78 | 0.28 % | $ 69.6 M | USA |